Ongoing drug safety monitoring is critical to containing risk and keeping patients safe, and with so many channels for reporting adverse events, the workload in processing cases is rising exponentially. But fit-for-purpose PV isn’t just about absorbing those extra volumes without driving up costs; it is also about maximising the positive impact of products for patients. This is especially true as ambitious new therapies enter markets with less predictable outcomes and side-effects over time. These converging requirements make harnessing AI non-negotiable, says Qinecsa’s Adam Sherlock.
